These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12932899)

  • 1. A structure-activity study of nociceptin-(1-13)-peptide amide. Synthesis of analogues substituted in positions 0, 1, 3, 4 and 10.
    Bobrova I; Vlaskovska M; Kasakov L; Surovoy A; Egorova N; Johansson L; Karsnas P; Terenius L
    Eur J Med Chem; 2003; 38(7-8):687-94. PubMed ID: 12932899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro agonist effects of nociceptin and [Phe(1)psi(CH(2)-NH)Gly(2)]nociceptin(1-13)NH(2) in the mouse and rat colon and the mouse vas deferens.
    Menzies JR; Glen T; Davies MR; Paterson SJ; Corbett AD
    Eur J Pharmacol; 1999 Dec; 385(2-3):217-23. PubMed ID: 10607879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.
    Guerrini R; Caló G; Lambert DG; Carrá G; Arduin M; Barnes TA; McDonald J; Rizzi D; Trapella C; Marzola E; Rowbotham DJ; Regoli D; Salvadori S
    J Med Chem; 2005 Mar; 48(5):1421-7. PubMed ID: 15743186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of [Tyr1]nociceptin analogs: receptor binding and bioassay studies.
    Varani K; Rizzi A; Calo G; Bigoni R; Toth G; Guerrini R; Gessi S; Salvadori S; Borea PA; Regoli D
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Sep; 360(3):270-7. PubMed ID: 10543428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH(2): identification of highly potent agonists of the nociceptin/orphanin FQ receptor.
    Guerrini R; Caló G; Bigoni R; Rizzi D; Rizzi A; Zucchini M; Varani K; Hashiba E; Lambert DG; Toth G; Borea PA; Salvadori S; Regoli D
    J Med Chem; 2001 Nov; 44(23):3956-64. PubMed ID: 11689082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides.
    Ambo A; Hamazaki N; Yamada Y; Nakata E; Sasaki Y
    J Med Chem; 2001 Nov; 44(23):4015-8. PubMed ID: 11689089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity studies on different modifications of nociceptin/orphanin FQ: identification of highly potent agonists and antagonists of its receptor.
    Chang M; Peng YL; Dong SL; Han RW; Li W; Yang DJ; Chen Q; Wang R
    Regul Pept; 2005 Sep; 130(3):116-22. PubMed ID: 15935490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ORL1 and opioid receptor preferences of nociceptin and dynorphin A analogues with Dmp substituted for N-terminal aromatic residues.
    Sasaki Y; Kawano S; Kohara H; Watanabe H; Ambo A
    Bioorg Med Chem; 2006 Apr; 14(7):2433-7. PubMed ID: 16321540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues. 1. In vitro studies.
    Bigoni R; Rizzi D; Rizzi A; Camarda V; Guerrini R; Lambert DG; Hashiba E; Berger H; Salvadori S; Regoli D; Calo' G
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Jun; 365(6):442-9. PubMed ID: 12070757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid receptor-like 1 (ORL1) receptor binding and the biological properties of Ac-Arg-Tyr-Tyr-Arg-Ile-Arg-NH2 and its analogs.
    Ambo A; Kohara H; Kawano S; Sasaki Y
    J Pept Sci; 2007 Oct; 13(10):672-8. PubMed ID: 17712865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activation.
    Nishimura H; Li J; Isozaki K; Okada K; Matsushima A; Nose T; Costa T; Shimohigashi Y
    Bioorg Med Chem; 2009 Aug; 17(15):5683-7. PubMed ID: 19577933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide.
    Guerrini R; Calo G; Rizzi A; Bianchi C; Lazarus LH; Salvadori S; Temussi PA; Regoli D
    J Med Chem; 1997 Jun; 40(12):1789-93. PubMed ID: 9191955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological activity of new series of N-modified analogues of the N/OFQ(1-13)NH2 with aminophosphonate moiety.
    Todorov PT; Mateeva PI; Zamfirova RN; Pavlov ND; Naydenova ED
    Amino Acids; 2012 Sep; 43(3):1217-23. PubMed ID: 22143428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phe1phi(CH2-NH)Gly2]nociceptin-(1-13)-NH2 acts as a partial agonist at ORL1 receptor endogenously expressed in mouse N1E-115 neuroblastoma cells.
    Olianas MC; Maullu C; Ingianni A; Onali P
    Neuroreport; 1999 Apr; 10(5):1127-31. PubMed ID: 10321496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist.
    Calo' G; Guerrini R; Bigoni R; Rizzi A; Bianchi C; Regoli D; Salvadori S
    J Med Chem; 1998 Aug; 41(18):3360-6. PubMed ID: 9719588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor binding properties and antinociceptive effects of chimeric peptides consisting of a micro-opioid receptor agonist and an ORL1 receptor antagonist.
    Kawano S; Ito R; Nishiyama M; Kubo M; Matsushima T; Minamisawa M; Ambo A; Sasaki Y
    Biol Pharm Bull; 2007 Jul; 30(7):1260-4. PubMed ID: 17603164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological studies of nociceptin derivatives containing the DTPA chelating group for further labeling with therapeutic radionuclides.
    Ligeti M; Gündüz O; Magyar A; Kató E; Rónai AZ; Vita C; Varga I; Hudecz F; Tóth G; Borsodi A; Benyhe S
    Peptides; 2005 Jul; 26(7):1159-66. PubMed ID: 15949634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of opioid receptor-like receptor ORL1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide.
    Shimohigashi Y; Hatano R; Fujita T; Nakashima R; Nose T; Sujaku T; Saigo A; Shinjo K; Nagahisa A
    J Biol Chem; 1996 Sep; 271(39):23642-5. PubMed ID: 8798582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion of delta-, kappa- and mu-receptor selective opioid peptide agonists into delta-, kappa- and mu-selective antagonists.
    Schiller PW; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Lu Y
    Life Sci; 2003 Jun; 73(6):691-8. PubMed ID: 12801590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro studies of the activity of newly sinthesized nociceptin / orphanin FQ receptor ligand analogues.
    Kasakov L; Nashar M; Naydenova E; Vezenkov L; Vlaskovska M
    Protein Pept Lett; 2010 May; 17(5):616-20. PubMed ID: 19689226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.